Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability, Food Effect and Pharmacokinetic Study of Deuremidevir Hydrobromide in Healthy Chinese Volunteers
NCT05932459Phase 1Completed
- Sponsor
- Vigonvita Life Sciences
- Start
- Jul 2023
- Primary completion
- Sep 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of deuremidevir in respiratory syncytial virus infection (RSV) (3 arms), sponsored by Vigonvita Life Sciences. Primary endpoints: Maximum Plasma Concentration at 48 hours, Area Under the Curve from Time 0 to Last Measurable Concentration at 48 hours and 7 more. Started Jul 2023; status: completed.
02
Drugs
deuremidevir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05932459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05932459.